A new non-invasive test for wet macular degeneration has been approved by the FDA. The new diagnostic test is known as the Foresee PHP (Preferential Hyperacuity Perimeter) can detect the early development of wet macular degeneration.
Wet macular degeneration is the leading cause of vision loss in people over 60 years of age, accounting for more than 90 percent of the blindness associated to the eye disease. The damage caused to the eye with this form of macular degeneration occurs rapidly as abnormal blood vessels grow and leak, causing scarring on the macula.
The Foresee PHP test significantly improves the detection of macular degeneration and provides eye care specialists with early detection, allowing treatments through anti-VEGF macular degeneration drugs such as Lucentis, Macugen or Avastin. Early detection of the eye disease means preventing damage to the eye.
The new non-invasive test for wet macular degeneration has the patients touching a touch-sensitive screen indicating where distortion occurs in a series of onscreen linear dots. Patients use a pointer similar to a pen and are required to simply indicate where the dots are out of line. The entire eye test takes approximately 20 minutes to perform and is non-invasive.
Early detection using the Forsee PHP test means halting the progression of the eye disease before damage becomes permanent. Early detection means early treatment, a critical component for providing eye care to those patients with wet macular degeneration.